Italy Biobanking Market Overview, 2029

Italy plays an important part in the nation's scientific and medical infrastructure, public health programmed, biomedical researchers, and a wide range of therapeutic applications, including biobanking. Biobanks hold a variety of biological samples, which includes tissues, blood, cells, and DNA, together with the corresponding clinical and demographic data. The use of such instruments and techniques facilitates the advancement of medical research, better patient care, and greater understanding of the causes of diseases. frequently connected to medical facilities, research centres, educational establishments, and biotechnology companies. Public biobanks collaborate with governmental agencies, educational institutions, and healthcare providers to support research projects, population health studies, and clinical trials. Personalized medical treatment, pharmaceutical development, and industry-specific research needs can all be served by private biobanks. In Italy, government is applied to operations with the goal of guaranteeing data security, patient privacy, and ethical behavior. The successful utilization of biobank resources necessitates cooperation among university, healthcare institutions, private companies and NGO's.

According to the research report " Italy Biobanking Market Overview, 2029," published by Bonafide Research, the Italy Biobanking market is anticipated to grow at more than 7% CAGR from 2024 to 2029. Several developments on personalized medicine, which helps to get medical treatments to individual patients based on their genetic makeup, lifestyle, and environmental factors, has led to an increased demand for high-quality biological samples and associated data. Biobanks play a crucial role in supporting personalized medicine initiatives by providing researchers and clinicians with access to diverse collections of samples for biomarker discovery, disease modeling, and treatment optimization. Continuous advancements in biomedical research have fulfilled the demand for biological samples for basic research, translational studies, and clinical trials. Biobanks provide researchers with access to well-characterized samples and associated data, enabling investigations into disease mechanisms, identification of therapeutic targets, and evaluation of drug efficacy and safety. There are the various types of products that are used in the biobanking sector. Equipment used to collecting, processing, storage, and analysis of biological samples is referred to as biobanking equipment. It includes a broad variety of tools. Sample collection, storage, and analysis, disposables are referred to as consumables. In order to successfully target various market groups, it also assists businesses in customizing their product offers and marketing plans. Moreover, it lets scholars and decision-makers examine patterns and advancements within each

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Ask an Expert

Manmayi Raval

Research Consultant

There are the several types of services provided in the biobanking sector in Spain, likewise cold chain logistics, lab processing, validation/qualification, biobanking and repositories, and others. Biological sample collection, processing, storage, and administration, as well as related data management, are all part of biobanking and repository services. For biological samples and related data kept in biobanks, validation and qualification services guarantee the quality, consistency, and dependability of the material. The tasks associated with sample preparation, analysis, and characterisation are included in the scope of lab processing services. Services for cold chain logistics make ensuring that biological samples are handled, transported, and stored properly at regulated temperatures to preserve the stability and integrity of the samples.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

In Italy, physical biobanks serve as crucial repositories for a myriad of biological samples, ranging from tissues to blood and DNA.These samples are stored in ultra-low temperature freezers or contemporary cryogenic tanks, which are designed to withstand harsh environments. The extensive collections that these organisations have amassed from people, patients, and other communities are a great resource for a variety of topics pertaining to clinical trials, biological research, and pharmaceutical initiatives in Italy. Physical biobanks offer a vast array of samples that are crucial for the comprehensive study of diseases, the identification of biomarkers, and the rigorous testing of potential therapeutic interventions to researchers across the country. However, virtual biobanks—also referred to as registry-based or data-driven biobanks—adopt a unique strategy.. Rather than storing physical samples, these innovative platforms house a wealth of biological data and associated information in digital or electronic formats. In Italy, virtual biobanks curate vast databases or registries brimming with anonymized health data, genetic insights, and other pertinent clinical or phenotypic records sourced from individuals or patient cohorts. Such platforms empower researchers across Italy to seamlessly access and analyze extensive datasets, facilitating comprehensive epidemiological studies, cutting-edge genetic research, and pivotal clinical trials. By sidestepping the need for physical sample handling, virtual biobanks enable population-scale analyses, spearhead precision medicine initiatives, and unearth novel associations within Italy's healthcare landscape. In Italy biobanks are important centers in the field of clinical research and medicine discovery i since they provide researchers with unrestricted access to a vast supply of biological samples. As a means of identifying therapeutic targets, figuring out how diseases work, and evaluating possible medications, these samples become invaluable resources. With the use of biobanking, scientists may carry out painstaking preclinical investigations, carefully select possible drugs, and thoroughly evaluate the safety and effectiveness of proposed therapies during clinical trials. Biobanking, therefore, is a key component in bringing novel findings from the lab bench to the clinic, therefore launching a new chapter in translational research initiatives throughout Italy. The environment of medicines development in Italy is greatly influenced by biobanks. Considered in this report • Historic year: 2018 • Base year: 2023 • Estimated year: 2024 • Forecast year: 2029 Aspects covered in this report • Biobanking market Outlook with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By Product Type • Equipment • Consumables • Laboratory Information Systems By Service Type • Biobanking and Repository • Validation/Qualification • Lab Processing • Cold Chain Logistic • Others By Biospecimen Type • Human Tissues • Stem Cells • Organs • Others By Biobank • Physical Biobanks • Virtual Biobanks By Application • Drug Discovery and Clinical Research • Therapeutics • Clinical Diagnostics • Others By Type of Biobank • Population-based Biobanks • Disease-oriented Biobanks By Ownership • National/regional agency • Non-Profit Organization • Universities • Private Organization By Storage • Manual Storage • Automated Storage The approach of the report: This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources. Intended audience This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the Biobanking industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.